Technology
Organoids are derived from biopsies and tissues sampled from patients or subjects (usually termed Patient-Derived Organoids, or PDOs). PDOs are self-organising cell structures that mimic the tissue or organ from which they are derived – they are often termed ‘mini-organs’.
PDOs provide a step-change improvement in the ability to screen drugs in models that are predictive of patient responses to those drugs, providing better data today and better drugs tomorrow.
- Derived in the lab from normal subjects or patient biopsy tissue from a wide variety of disease states
- 3D clusters, self-assembled from adult stem cells with no planar plasticisation
- Contain multiple cell-types
- Mimic source organ/tissue architecture to duplicate normal or disease pathology
Cellesce’s leading technology can:
Produce millions of reproducible PDOs per manufacturing batch using its patented bioprocess and bioreactors.
Genetically diverse
Can be used in diagnostics and personalised medicine
Faithful & predictive
Can model by tumour or mutation subtype
Multicellular & 3D
Can be used in diagnostics and personalised medicine
Model major tissue types
Wide range of cancer types, normal tissue – other therapies
Scalable & consistent
Can be used in high throughput applications
Can add immune cells
Can use in immune & cell therapy applications
The Cellesce Organoid Expansion Process
Cellesce has invented and patented a novel bioprocess for the expansion of PDOs for a multitude of applications including drug discovery, biological drug targeting and organ-on-a-chip applications.
Until recently, organoids could only be grown and expanded manually. This is a technically challenging, time-consuming, and labour-intensive process resulting in small numbers of PDOs with inconsistent performance. This has previously limited PDO suitability for use in high throughput and other applications by pharma and biotech.
The patented Cellesce bioprocess has enabled a massive increase in PDO production compared to manual processes. Furthermore, better process controls utilising in-line sensors and real-time monitoring ensure precise culture conditions, improved yield and control of PDO size and reduced batch-to-batch, user-to-user variability. Cellesce’s significant improvement to existing bulk culture methods has finally enabled PDOs for drug discovery and development.
